Adjuvant Therapies of Cancer

1. Front Matter

   Pages I-XVI

   PDF

2. General Considerations

   1. Metastatic Potential of Metastases, Tumor Cell Heterogeneity, and Therapeutic Implications

      • F. Spreafico, A. Mantovani, R. Giavazzi, G. Conti, A. Anaclerio

      Pages 1-8

   2. Immune Imbalance and Immune Modulation in Solid Tumor Patients: New Insights

      • B. Serrou, D. Cupissol, C. Rosenfeld

      Pages 9-16

   3. Markers of Minimal Residual Disease

      • A. M. Neville

      Pages 17-21

   4. Radiotherapy as Adjuvant Local Therapy of Local Tumors

      • D. Chassagne

      Pages 22-25

3. Hemopoietic and Lymphoid Neoplasias

   1. Comparison of HLA Phenotypes in Long-Term Survivors with Acute Lymphoblastic Leukemia Treated with Immunotherapy Versus Chemotherapy

      • T. Tursz, J. Hors, M. Lipinski, J.-L. Amiel, G. Mathé

      Pages 26-28

   2. An Intensive Chemo- or Chemoimmunotherapy Regimen for Patients with Intermediate and Poor-Prognosis Acute Lymphatic Leukemia and Leukemic Lymphoblastic Lymphosarcoma: Preliminary Results with 14-Month Median Follow-Up

      • J. L. Misset, F. De Vassal, M. Delgado, P. Ribaud, M. Musset, T. Dorval et al.

      Pages 29-35

   3. Poor-Prognosis Acute Lymphoblastic Leukemias

      • M. Weil, C. Jacquillat, M. F. Auclerc, G. Schaison, C. Chastang, J. Bernard

      Pages 36-41

   4. Therapeutic Effectiveness of Neuraminidase-Treated Allogeneic Myeloblasts as Immunogen in Acute Myelocytic Leukemia

      • J. G. Bekesi, J. F. Holland

      Pages 42-55

   5. Maintenance Chemoimmunotherapy of Nonlymphoblastic Acute Leukemias

      • R. Favre, G. Sebahoun, D. Bagarry-Liégey, C. Imbert, P. Ciardelli, J. A. Gastaut et al.

      Pages 56-63

   6. Possible Mechanisms of Immunotherapy Action in Acute Nonlymphatic Leukemia: Macrophage Production of Colony-Stimulating Activity

      • P. Reizenstein, B. Andersson, M. Beran

      Pages 64-69

   7. The Finnish Leukaemia Group: Levamisole in Maintenance Therapy of Acute Myeloid Leukemia in Adults

      • M. Lehtinen, P. Ahrenberg, A. Hänninen, E. Ikkala, R. Lahtinen, A. Levanto et al.

      Pages 70-72

   8. Treatment of Acute Leukemia in Remission by Bone Marrow Transplantation

      • R. Storb

      Pages 73-77

   9. Prevention of Blastic Crisis in Ph1-Positive Chronic Myeloid Leukemia

      • J. C. Sharp

      Pages 78-82

   10. A Southwest Oncology Group: Chemotherapy Versus Chemotherapy Plus Radiotherapy in Treatment of Stage III Hodgkin’s Disease

       • P. N. Grozea, E. J. De Persio, C. A. Coltman Jr., C. J. Fabian, F. S. Morrison, E. A. Gehan et al.

       Pages 83-91

   11. Maintenance Immunotherapy with BCG in Non-Hodgkin’s Malignant Lymphomas: A Progress Report of a Randomized Trial

       • B. Hœrni, M. Durand, H. Eghbali, G. Hœrni-Simon, P. Richaud, A. de Mascarel

       Pages 92-97

4. Bone Tumors

   1. Role of Lung Irradiation in the Adjuvant Treatment of Osteosarcoma

      • E. van der Schueren, K. Breur

      Pages 98-102

   2. Adjuvant Interferon Treatment of Human Osteosarcoma

      • H. Strander, T. Aparisi, H. Blomgren, L. Å. Broström, K. Cantell, S. Einhorn et al.

      Pages 103-107

   3. A Strategic Adjuvant Therapy of Osteosarcoma

      • C. Jasmin

      Pages 108-114

   4. Ewing’s Sarcoma: Treatment with High-Dose Radiation and Adjuvant Chemotherapy

      • A. Goldman

      Pages 115-119

Transplantation of syngeneic (donor is a monozygous twin) or allogeneic (donor is an HLA-identical sibling) marrow provides the opportunity for aggressive antileukemic therapy without regard to marrow toxicity. Until 1975, marrow transplantation was carried out only after failure of all other therapy. Consequently, most patients were in advanced relapse. Six of 16 recipients of syngeneic marrow and 13 of 100 recipients of allogeneic marrow are still in remission after 5. 5-10 years [3, 7]. An actuarial survival curve of the first 100 patients grafted in Seattle after conditioning with cyclophos­ phamide (60 mg/kg on each of 2 successive days) and total body irradiation (1,000 rad) showed three periods of interest: (1) The first 4 months showed a rapid loss of patients associated with advanced illness, graft-versus-host disease, infections (in particular interstitial pneumonias), and recurrent leukemia; (2) from 4 months to 2 years, the curve showed a much slower rate of decline attributable primarily to recurrent leukemia; and (3) from 2-10 years, the curve was almost flat with a negligible loss of patients and no recurrent leukemia. This flat portion of the curve corresponded to 13% of the patients and indicates a strong probability that the majority of these survivors are cured of their disease [8]. Attempts at reducing the incidence of leukemic relapse after transplantation were made by a number of marrow transplant groups by added chemotherapy.

• Immunotherapie
• Krebs
• Strahlentherapie
• Zytostatikum
• cancer
• chemotherapy
• leukemia
• radiation
• transplantation
• Radiaton Oncology

• Institut de Cancérologie et d’Immunogénétique, Hôpital Paul-Brousse, Villejuif, France

  G. Mathé

• Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

  G. Bonadonna

• Health Science Center Department of Internal Medicine Section of Hematology and Oncology Tucson, The University of Arizona, USA

  S. Salmon

Policies and ethics